Small Cap Feast
Small Cap Feast – 17 March 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
Sirius Minerals has left the Main Market. following a takeover. Summit Properties has left AIM
Sirius Minerals has left the Main Market. following a takeover. Summit Properties has left AIM
What’s Cooking in the IPO Kitchen?
Main Market (Standard List)
Abal Group (formerly on AIM) to relist as Supply@Me, a growing innovative “inventory monetisation” platform, having originated more than EUR300m of prospective “inventory monetisation deals” in its first six months of operating (to June 2018). In the first half of 2019, an additional prospective EUR300m was originated. As at the date of the publication of the Prospectus and Circular to Abal shareholders, dated 4 March 2020 , EUR972m of prospective contracts have been originated. Raising £2.2m. Due 23 March.
Main Market (Premium)
DRI Healthcare—investment company focused on investments in healthcare Royalty Assets looking to raise $350m. Timetable now extended.
Litigation Capital Management (LIT.L) 49.25p £56.6m
HY Dec20 results from the international provider of disputes financing solutions.
Delivering sustained growth across a diversified portfolio by investment activity and geography
First close of a new third-party fund of US$150m (post-period)
Cumulative 139% ROIC and 79% IRR over the last 8.5 years
Total cash generated of A$18.9 million (post-period cash receipt totalling A$9.7 million)
Four single-case investments in APAC generated a combined revenue of approximately A$14.9 million and contribution to gross profit of approximately A$7.8 million
First matter resolution in the aviation portfolio; generated revenue of A$0.6 million and provided a contribution to gross profit of A$0.2 million
Strategic Alliance with international law firm delivered material opportunities and over 30 applications, including both single case and corporate portfolio. Second Alliance initiated with an international law firm which has already generated corporate portfolio applications
Seeing Machines (SEE.L) 1.575p £53m
COVID-19 Update. There is an underlying and unstoppable movement for improved safety across all industry verticals and transport sectors, globally. Seeing Machines’ driver monitoring system technology benefits significantly from this and expects to continue to do so in the medium and long term.
The immediate global impact from COVID-19 is unprecedented and, as governments across the world make a number of significant decisions on a day-to-day basis and implement a range of precautionary measures, many of which impinge on the movement of people and goods, this presents an obvious challenge to the transport sectors which Seeing Machines’ technology and products serve.
Accordingly, despite the otherwise positive momentum across all transport sectors and significant confirmed order books for both the Fleet and Automotive divisions, the short to medium-term outlook is uncertain and it is possible that the Company will be impacted by these conditions.
Cambridge Cognition (COG.L) 21.3p £6.6m
Cambridge Cognition Holdings plc , which develops and markets digital solutions to assess brain health, announced that the Company has won a contract for three phase II studies with a new pharmaceutical client The Directors believe these studies, which have an aggregate value to the Company of £1.37 million, demonstrate significant progress for the Company in delivering its strategy of combining the sale of CANTAB™ cognitive assessments with additional electronic clinical outcome assessments (eCOA). Contract delivery is expected to be over a two year period.
The three studies will include a total of 180 patients – 60 per clinical group – with the overall objective being to track early cognitive changes and motor signals associated with the drug being delivered. By delivering CANTABTM cognitive assessments and eCOA questionnaires and scales all one platform, the Client will be able to sensitively, efficiently and securely monitor three distinct clinical populations.
Osirium (OSI.L) 19.5p £3.8m
The vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a major regional UK Ambulance Service.
The new client has purchased a 60 month term license for 250 devices for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. Consultancy and training from Osirium Professional Services are included in the contract.
The Osirium PAM platform has been selected in a public sector tender bid as part of a sales initiative led jointly by Osirium and an approved reseller partner. The principal d rivers for the client on this project are securing and controlling access to the infrastructure by 3rd party contractors and vendors, implementing secure access for internal staff to privileged accounts, and managing service accounts in line with policy. The client will be making full use of Osirium Task Automation to ‘Shift Left’ or delegate IT tasks to junior IT team members and free up senior IT staff to focus on complex projects
Blackbird (BIRD.L) 7.75p £26m
The developer and seller of the market-leading cloud video editing platform, Blackbird, today launched its Virtual pre-NAB 2020 focused on enabling live or file-based remote video editing for enterprises.
Enterprises responding to the global threat of Coronavirus that need to enable remote or home editing for all or part of their content creation teams are invited to book an online demonstration of Blackbird on either 25 or 26 March 2020. There will also be a selection of group masterclasses available.
Blackbird can, very easily, enable highly responsive and fully featured remote editing for live and file-based content and can be used with a standard laptop. Built for the cloud, Blackbird is the only professional video editor in a browser. Video production staff can work with Blackbird from home or any other location with all the professional standard editing tools they need – even on low bandwidth.
Ethernity Networks (ENET.L) 32p £10.46m
The supplier of data processing offload solutions on programmable hardware for accelerating telco/cloud networks, today introduced its ENET-D, an add-on Ethernet Controller technology to its ACE-NIC100 SmartNIC that efficiently processes millions of data flows and offers performance acceleration for networking and security appliances.
ENET-D is an Ethernet adapter and DMA (direct memory access) engine that eliminates the need for proprietary hardware on a network interface card. By fitting into various FPGAs and enabling customers to further avoid ASIC-based components, ENET-D advances complete disaggregation at the edge of the network .
Xeros Tech Grp (XSG.L) 0.425p £3.3m
The developer and provider of water saving and filtration technologies with multiple commercial applications, announces today that it has signed a Joint Development Agreement (“JDA”) with a global leader in commercial laundry solutions, with the aim of incorporating the Company’s microplastic filtration system, XFiltraTM, into their commercial washing machines. Washing textiles containing synthetic fibres, such as nylon or polyester, is a major source of microplastic pollution. Globally, it accounts for 35% of primary microplastics released into the oceans every year. As many as 700,000 microplastic fibres can be released in the wastewater from a single load of domestic laundry.
Xeros’ patented filtration system, XFiltra removes up to 99% of these microplastic fibres from laundry effluent. he device lasts for the lifetime of the washing machine and does not use disposable filter cartridges.
Everyman Media (EMAN.L) 70p £51.5m
As announced on 15 January 2020, the Company had a good 2019 demonstrating the strength of the Everyman brand and financial model. The Company intends to release full year results for the financial year ended 2 January 2020 on 19 March 2020.
Trading over recent days has been impacted by COVID-19 and the delay of major movie releases. Following guidance provided by the UK government yesterday, the Board of Everyman has taken the decision to close its venues to guests until further notice. The health of our staff and our customers is the boards highest priority.
Whilst site closures will clearly have an impact on the Group’s ability to operate whilst restrictions are in place, this does not change the Board’s confidence in Everyman and its proposition over the long term.
Best of the Best (BOTB.L) 405p £38m
Trading update from the online organiser of weekly competitions to win cars and other lifestyle prizes, is pleased to provide the following trading update. As announced at the time of its Interim Results, the Company has experienced a strong start to the H2 and the Board reportx that this momentum has continued.
The Board has continued to drive investment across all marketing channels and this increased spend has led to a rise in customer engagement and new customer acquisition. As such, the Company is pleased to advise that it is currently trading ahead of market guidance, as updated on 30 January 2020, in respect of both full year revenue and profit.
Nu-Oil and Gas (NUOG.L) 0.0225p £0.77m
The AIM Rule 15 cash shell, has updated shareholders.
As a result of, inter alia, commodity price volatility over several months and, more specifically, the last few weeks, the Company is evaluating potential reverse takeover targets across all sectors and not solely in oil and gas, which had been the Company’s intended target space as announced on 11 October 2019.
The Company has particularly focused its efforts on the environmental industries sector and is pleased to confirm that it is in discussions with several potential targets.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.